Mr. Irwin Simon reports
APHRIA ADDS TO PLANNED PORTFOLIO OF VAPES & CONCENTRATES WITH PAX LABS AGREEMENT
Aphria Inc. has signed an agreement with San Francisco-based PAX Labs Inc., a leader in the design and development of premium cannabis vaporization devices, that will enable Aphria to provide premium cannabis extracts in pods designed for use with PAX's innovative Era device and platform. The company plans to introduce PAX pods for both adult-use consumers and medical patients, pending anticipated changes to the Cannabis Act to permit the sale of cannabis extracts for vaporization.
"As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis into their lives," said Irwin Simon, interim chief executive officer of Aphria. "We are excited to bring our premium cannabis extracts from Solei, Riff and our flagship medical cannabis brand, Aphria, to the PAX Era device and platform."
PAX has already sold more than 500,000 Era devices for oil concentrates in the United States and continues to see expansive growth.
"The expected legalization of vapes and concentrates will mark a significant turning point in the Canadian market, providing more choice and new experiences while opening the door to a range of new consumers," added Mr. Simon. "Our strategic alliance with PAX sets the stage for our broad portfolio of vapes and concentrate products to come."
Aphria estimates vapes and concentrates will represent close to 30 per cent of the entire Canadian adult-use market by 2021.
"This collaboration complements Aphria's growing roster of strategic innovation partners, including Manna Molecular Sciences and Rapid Dose Therapeutics, as we pursue new innovations that will change the way consumers interact with cannabis in the future," said Mr. Simon.
About Aphria Inc.
Aphria is a leading global cannabis company driven by an unrelenting commitment to its people, the planet, product quality and innovation. Headquartered in Leamington, Ont., the greenhouse capital of Canada, Aphria has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Rooted in its founders' multigenerational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across five continents.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.